指南与共识呼吸道感染肺栓塞与肺血管病呼吸危重症与机械通气

COVID-19患者血栓预防:CHEST指南与专家小组报告简要更新

Thromboprophylaxis in Patients With COVID-19: A Brief Update to the CHEST Guideline and Expert Panel Report.
指南 / 共识 · Chest · 2022-02-12

该更新基于8项随机对照试验和1项观察性研究,采用GRADE框架和改良Delphi法,针对COVID-19住院患者血栓预防提出更新建议。将原问题拆分为标准预防对比治疗剂量(或升级剂量)预防、标准预防对比中间剂量预防,导致1条推荐改变、3条推荐升级。结论认为危重症患者应接受标准血栓预防,出血风险低的急性中度病患者可能受益于治疗剂量肝素,中间剂量预防在两种情况下均无角色。

要点

  • 危重症COVID-19患者应接受标准剂量血栓预防。
  • 出血风险低的急性中度病COVID-19患者可能受益于治疗剂量肝素。
  • 中间剂量血栓预防在危重症和中度病患者中均无角色。

核心结论

  • 危重症COVID-19患者应接受标准血栓预防,出血风险低的急性中度病患者可能受益于治疗剂量肝素,中间剂量预防在两种情况下均无角色。

研究设计与样本

  • 本更新聚焦住院患者血栓预防的最优策略,通过PubMed检索MEDLINE,纳入8项随机对照试验和1项观察性研究,采用随机效应模型进行Meta分析,并使用GRADE证据到决策框架和改良Delphi法达成共识。

主要发现

  • 将每个原始问题及推荐拆分为标准预防对比治疗剂量(或升级剂量)预防、标准预防对比中间剂量预防两个问题。
  • 基于更高质量证据,导致1条推荐改变,3条额外推荐升级。

关键数值与推荐

  • 危重症患者应接受标准血栓预防。
  • 出血风险低的急性中度病患者可能受益于治疗剂量肝素。
  • 中间剂量血栓预防在危重症和中度病情况下均无角色。

临床怎么用

  • 对COVID-19住院患者,危重症者使用标准剂量血栓预防。
  • 对急性中度病且出血风险低的患者,可考虑治疗剂量肝素。
  • 不推荐使用中间剂量血栓预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients hospitalized with COVID-19 often exhibit markers of a hypercoagulable state and have an increased incidence of VTE. In response, CHEST issued rapid clinical guidance regarding prevention of VTE. Over the past 18 months the quality of the evidence has improved. We thus sought to incorporate this evidence and update our recommendations as necessary. STUDY DESIGN AND METHODS: This update focuses on the optimal approach to thromboprophylaxis in hospitalized patients. The original questions were used to guide the search, using MEDLINE via PubMed. Eight randomized controlled trials and one observational study were included. Meta-analysis, using a random effects model, was performed. The panel created summaries using the GRADE Evidence-to-Decision framework. Updated guidance statements were drafted, and a modified Delphi approach was used to obtain consensus. RESULTS: We provide separate guidance statements for VTE prevention for hospitalized patients with acute (moderate) illness and critically ill patients in the ICU. However, we divided each original question and resulting recommendation into two questions: standard prophylaxis vs therapeutic (or escalated dose) prophylaxis and standard prophylaxis vs intermediate dose prophylaxis. This led to a change in one recommendation, and an upgrading of three additional recommendations based upon higher quality evidence. CONCLUSIONS: Advances in care for patients with COVID-19 have improved overall outcomes. Despite this, rates of VTE in these patients remain elevated. Critically ill patients should receive standard thromboprophylaxis for VTE, and moderately ill patients with a low bleeding risk might benefit from therapeutic heparin. We see no role for intermediate dose thromboprophylaxis in either setting.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Moores LK, Tritschler T, Brosnahan S, et al. Thromboprophylaxis in Patients With COVID-19: A Brief Update to the CHEST Guideline and Expert Panel Report. Chest. 2022. PMID: 35167861. doi:10.1016/j.chest.2022.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。